Last updated: 2026-10-12 15:16:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Liquidia Corporation (LQDA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $27.95, with a market capitalization of $2.45B and a P/E ratio of 17.68. Over the past 52 weeks, its price has ranged from $21.94 to $93.61. This page covers its latest market performance, valuation, price trends and company information.
$2.45B | |
$29.27 | |
$93.61 | |
$2.25 | |
$27.38 | |
1.80M | |
2.51M | |
17.68 | |
$93.61 | |
$21.94 | |
-- | |
-- |
Liquidia Corporation (LQDA) is currently trading at $27.95 as of 2026-10-12 15:00:01, up 2.07% ($0.57) from the previous close of $27.38
During today's regular trading session, LQDA has traded between $2.25 and $93.61, with a trading volume of 1.80M shares. The current price is near the lower end of today's range.
Over the past seven days, Liquidia Corporation (LQDA) moved from $27.99 to $27.95, representing a decline of 0.16% ($0.04).
The stock traded between $22.31 and $30.77 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 8.42 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 8.4%
LQDA is currently trading at $27.95, placing it 8.4% of the way from its 52-week low of $21.94 to its 52-week high of $93.61. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 216 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Liquidia Corporation (LQDA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.